Duyuru • Mar 31
Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Duyuru • Mar 19
Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026 Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China Duyuru • Dec 31
Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026 Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026 Duyuru • Nov 15
Imeik Technology Development Co.,Ltd. Announces Directorate Appointments Imeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director. Duyuru • Sep 30
Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Duyuru • Aug 21
Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025 Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025. Duyuru • Jul 02
Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025 Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025 Duyuru • Apr 22
Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024 Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024. Duyuru • Mar 31
Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Duyuru • Mar 20
Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025 Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China Duyuru • Dec 31
Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025 Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥1.54 (vs CN¥1.51 in 3Q 2023) Third quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to CN¥212, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥288 per share. Buy Or Sell Opportunity • Oct 11
Now 24% undervalued Over the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Duyuru • Sep 30
Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share. Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥139, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥277 per share. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥1.97 (vs CN¥1.82 in 2Q 2023) Second quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Duyuru • Jun 29
Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024 Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024 New Risk • Apr 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (39% increase in shares outstanding). Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥2.45 (vs CN¥1.91 in 1Q 2023) First quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share. Duyuru • Mar 30
Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Duyuru • Mar 20
Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024 Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China Reported Earnings • Mar 20
Full year 2023 earnings released: EPS: CN¥8.60 (vs CN¥5.84 in FY 2022) Full year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Buy Or Sell Opportunity • Mar 16
Now 20% undervalued Over the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 45% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥410 per share. Buy Or Sell Opportunity • Jan 19
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥424 per share. Duyuru • Dec 29
Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024 Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024 Duyuru • Sep 15
Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023 Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000. Reported Earnings • Aug 27
Second quarter 2023 earnings released: EPS: CN¥2.54 (vs CN¥1.43 in 2Q 2022) Second quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Duyuru • Aug 26
Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023 Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000. Board Change • Jul 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Duyuru • Jun 13
Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares. Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.